Indexed in

License and use

Citations

Cited 2 times in

Altmetrics

Analysis of institutional authors

Share

Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study

Publicated to:Minerva Anestesiologica. 88 (4): 259-271 - 2022-04-01 88(4), DOI: 10.23736/s0375-9393.22.15942-0

Authors: Zattera L; Veliziotis I; Benítez-Cano Martínez A; Ramos I; Larrañaga L; Nuñez M; Román L; Adalid I; Ferrando C; Muñoz G; Arruti E; Minini A; Bassas E; Hernández M; Taccone FS; Peluso L; Adalia R; Abad Motos A; Abad-Gurumeta A; Acevedo Bambaren IA; Adalia R; Adalid Hernandez I; Aguilar G; Aguilera Cuchillo L; Agulló AJ; Agustí M; Albala Blanco MI; Alberdi Enríquez A; Albericio Gil B; Alcon A; Alday Mlñoz E; Aldecoa C; Algar Yañez B; Aliaga J; Almuedo A; Alonso JR; Alonso Montoiro P; Alonso Portela M; Alonso Viejo O; Álvarez Campo A; Álvarez García JC; Álvarez Herreros C; Alvarez Pereira J; Álvarez Utrera F; De Borja Amador Penco F; Andrea R; Andrés J; Apodaka López N; Aponte Sierra A; Aracil Escoda N; Arguís MJ; Arias A; Arias M; Armero Ibañez R; Arribas Méndez D; Artaza Aparicio L; Avellanosa Esteruelas J; Aziz F; Azzam López A; Bachs Almenara F; Badía JR; Bainac A; Baladron González V; Balaguer M; Balibrea JM; Balust J; Balvis AJ; Barba Orejudo A; Barbeta E; Barbier Damborenea P; Bárcena Andrés E; Bardi T; Barreiro Aragunde S; Bassas Parga E; Batiste G; De Borja Bau González F; Bejarano Ramírez N; Belda I; Beltrán De Heredia S; Beltrán Martín M; Benatar Haserfaty J; Benet P; Bengoetxea U; Bergé R; Bernia Gil JA; Berruezo Camacho A; Betolaza Weimer L; Bilbao Villas Ante I; Blanco Alcaide L; Bordell A; Borja De Lacy F; Borrat X; Borrell M; Bragulat E; Bravo R; Briones Orejliela C; Buenaventura Sanclemente G; Caballero A; Callalt Calvo A; Calvo A

Affiliations

Abstract

BACKGROUND: High levels of procalcitonin (Pct) have been associated with a higher risk of mortality in coViD-19 patients. We explored the prognostic role of early Pct assessment in critically ill coViD-19 patients and whether Pct predictive performance would be influenced by immunosuppression. METHODS: retrospective multicentric analysis of prospective collected data in coViD-19 patients consecutively admitted to 36 intensive care units (icUs) in spain and andorra from March to June 2020. adult (>18 years) patients with confirmed COVID-19 and available PCT values (<72 hours from ICU admission) were included. Patients were considered as “no immunosuppression” (Ni), “chronic immunosuppression” (ci) and “acute immunosuppression” (ait if only tocilizumab; ais if only steroids, aits if both). the primary outcome was the ability of Pct to predict icU mortality. RESULTS: of the 1079 eligible patients, 777 patients were included in the analysis. Mortality occurred in 227 (28%) patients. in the Ni group 144 (19%) patients were included, 67 (9%) in the ci group, 66 (8%) in the ait group, 262 (34%) in the AIS group and 238 (31%) in the AITS group; PCT was significantly higher in non-survivors when compared with survivors (0.64 [0.17-1.44] vs. 0.23 [0.11-0.60] ng/mL; P<0.01); however, in the multivariable analysis, PCT values was not independently associated with ICU mortality. PCT values and ICU mortality were significantly higher in patients in the Ni and ci groups. CONCLUSIONS: Pct values are not independent predictors of icU mortality in coViD-19 patients. acute immunosuppression significantly reduced PCT values, although not influencing its predictive value.

Keywords